Interpreting EMPOWER-Lung 3: Key Endpoints and Confidence in Cemiplimab-Based Therapy

This episode, titled Interpreting EMPOWER-Lung 3: Key Endpoints and Confidence in Cemiplimab-Based Therapy, features lung cancer experts answering the following critical questions:

• What are your main takeaways from the data covered?
• Which of the endpoints examined are most important for your clinical practice and why?
• Does the consistent benefit with cemiplimab plus chemotherapy across the different subgroups increase your confidence?

Led by the moderator, the panelist examined the 5-year data from the EMPOWER-Lung 3, which reinforces the durability of benefit with cemiplimab plus chemotherapy, demonstrating sustained improvements in overall survival and long-term outcomes in patients with advanced non-small cell lung cancer. A key takeaway is that the survival benefit is not only statistically significant but also clinically meaningful over time, supporting the regimen as a foundational first-line option. The consistency of efficacy across multiple patient subgroups, including varying levels of PD-L1 expression and both squamous and non-squamous histologies, highlights its broad applicability in real-world settings.

In clinical practice, overall survival remains the most important endpoint because it directly reflects meaningful patient benefit, while progression-free survival and response rates provide supportive insights into disease control. Long-term survival data, such as 5-year outcomes, are particularly valuable in understanding the durability of immunotherapy responses and guiding treatment expectations. The consistent benefit observed with cemiplimab plus chemotherapy across diverse subgroups further increases confidence in its use, as it suggests reliable efficacy regardless of key baseline characteristics.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Optimizing Immunotherapy Selection and Safety Management in NSCLC, panelists will continue their discussion on treatment selection in non-small cell lung cancer, which is guided by factors such as PD-L1 expression, disease burden, comorbidities, and the need for rapid response, with monotherapy often reserved for high PD-L1 tumors and chemoimmunotherapy favored for broader or more symptomatic populations. Ongoing monitoring for immune-related adverse events—paired with early intervention strategies—and the consistent long-term safety profile of cemiplimab plus chemotherapy enhance confidence in its clinical value and support its use as a reliable first-line option.